Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03939637 · ClinicalTrials.gov registry record · Phase 3
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
A Phase 3 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
NCT03939637 is a Phase 3 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 122 participants.
The verdict
NCT03939637, a Phase 3 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
Study Summary
This is an investigator initiated, multicenter, open label, randomized phase 3 study for subjects with newly diagnosed ITP from ages 1 to less than 18 years old.
Interventions
- DRUG Eltrombopag
- DRUG IVIG
- DRUG Steroids
- DRUG Rho(D) Immune Globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2025-02-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03939637
The ClinicalTrials.gov registry entry for NCT03939637 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Eltrombopag is the first listed.
NCT03939637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03939637 about?
NCT03939637 is a clinical study titled "Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children". This is an investigator initiated, multicenter, open label, randomized phase 3 study for subjects with newly diagnosed ITP from ages 1 to less than 18 years old.
What is the current status of trial NCT03939637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2019-05-02. Estimated completion is 2025-02-26.
What interventions are being tested in trial NCT03939637?
The interventions under investigation include: Eltrombopag (DRUG), IVIG (DRUG), Steroids (DRUG), Rho(D) Immune Globulin (DRUG).
Who is sponsoring clinical trial NCT03939637?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.